Figure S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis | Synapse
August 4, 2025
Figure S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Key Points
PLT012, a humanized CD36-blocking antibody, enhances antitumor immunity against liver cancer.
The study characterizes tumor-infiltrating lymphocytes and gene signatures following treatment with PLT012.
Liver cancer mouse models showed increased immune activity against tumors post-PLT012 administration.
These findings provide insights for potential therapeutic strategies targeting liver cancer and metastasis.
Abstract
Characterization for TILs population and gene signatures in liver cancer mouse models following PLT012 treatment.